Overexpression of Peptide Deformylase in Breast, Colon, and Lung Cancers

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2013 Jul 3

PMID 23815882

Citations 14

Authors

Harsharan Randhawa

Shireen Chikara

Drew Gehring

Tuba Yildirim

Jyotsana Menon

Katie M Reindl

Affiliations

Soon will be listed here.

Abstract

Background: Human mitochondrial peptide deformylase (PDF) has been proposed as a novel cancer therapeutic target. However, very little is known about its expression and regulation in human tissues. The purpose of this study was to characterize the expression pattern of PDF in cancerous tissues and to identify mechanisms that regulate its expression.

Methods: The mRNA expression levels of PDF and methionine aminopeptidase 1D (MAP1D), an enzyme involved in a related pathway with PDF, were determined using tissue panels containing cDNA from patients with various types of cancer (breast, colon, kidney, liver, lung, ovarian, prostate, or thyroid) and human cell lines. Protein levels of PDF were also determined in 2 colon cancer patients via western blotting. Colon cancer cells were treated with inhibitors of ERK, Akt, and mTOR signaling pathways and the resulting effects on PDF and MAP1D mRNA levels were determined by qPCR for colon and lung cancer cell lines. Finally, the effects of a PDF inhibitor, actinonin, on the proliferation of breast, colon, and prostate cell lines were determined using the CyQUANT assay.

Results: PDF and MAP1D mRNA levels were elevated in cancer cell lines compared to non-cancer lines. PDF mRNA levels were significantly increased in breast, colon, and lung cancer samples while MAP1D mRNA levels were increased in just colon cancers. The expression of PDF and MAP1D varied with stage in these cancers. Further, PDF protein expression was elevated in colon cancer tissue samples. Inhibition of the MEK/ERK, but not PI3K or mTOR, pathway reduced the expression of PDF and MAP1D in both colon and lung cancer cell lines. Further, inhibition of PDF with actinonin resulted in greater reduction of breast, colon, and prostate cancer cell proliferation than non-cancer cell lines.

Conclusions: This is the first report showing that PDF is over-expressed in breast, colon, and lung cancers, and the first evidence that the MEK/ERK pathway plays a role in regulating the expression of PDF and MAP1D. The over-expression of PDF in several cancers and the inhibition of cancer cell growth by a PDF inhibitor suggest this enzyme may act as an oncogene to promote cancer cell proliferation.

Citing Articles

COL25A1 and METAP1D DNA methylation are promising liquid biopsy epigenetic biomarkers of colorectal cancer using digital PCR.

Overs A, Peixoto P, Hervouet E, Molimard C, Monnien F, Durand J Clin Epigenetics. 2024; 16(1):146.

PMID: 39425144 PMC: 11490026. DOI: 10.1186/s13148-024-01748-1.

Cytosolic N-terminal formyl-methionine deformylation derives cancer stem cell features and tumor progression.

Kim D, Lee J, Seok O, Lee Y, Hwang C Sci Rep. 2024; 14(1):14900.

PMID: 38942903 PMC: 11213908. DOI: 10.1038/s41598-024-65701-1.

Structural insights into N-terminal methionine cleavage by the human mitochondrial methionine aminopeptidase, MetAP1D.

Lee Y, Kim H, Lee E, Hahn H, Heo Y, Jang D Sci Rep. 2023; 13(1):22326.

PMID: 38102161 PMC: 10724148. DOI: 10.1038/s41598-023-49332-6.

Impact of Protein N-Modifications on Cellular Functions and Human Health.

Chang Y Life (Basel). 2023; 13(7).

PMID: 37511988 PMC: 10381334. DOI: 10.3390/life13071613.

Therapeutic potential of human serum albumin nanoparticles encapsulated actinonin in murine model of lung adenocarcinoma.

Ahlawat P, Phutela K, Bal A, Singh N, Sharma S Drug Deliv. 2022; 29(1):2403-2413.

PMID: 35892161 PMC: 9336490. DOI: 10.1080/10717544.2022.2067600.

References

Giglione C, Meinnel T . Peptide deformylase as an emerging target for antiparasitic agents. Expert Opin Ther Targets. 2005; 5(1):41-57. DOI: 10.1517/14728222.5.1.41. View

Serero A, Giglione C, Meinnel T . Distinctive features of the two classes of eukaryotic peptide deformylases. J Mol Biol. 2001; 314(4):695-708. DOI: 10.1006/jmbi.2001.5175. View

Escobar-Alvarez S, Goldgur Y, Yang G, Ouerfelli O, Li Y, Scheinberg D . Structure and activity of human mitochondrial peptide deformylase, a novel cancer target. J Mol Biol. 2009; 387(5):1211-28. PMC: 2782631. DOI: 10.1016/j.jmb.2009.02.032. View

Lee M, She Y, Soskis M, Borella C, Gardner J, Hayes P . Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics. J Clin Invest. 2004; 114(8):1107-16. PMC: 522256. DOI: 10.1172/JCI22269. View

Nguyen K, Hu X, Colton C, Chakrabarti R, Zhu M, Pei D . Characterization of a human peptide deformylase: implications for antibacterial drug design. Biochemistry. 2003; 42(33):9952-8. DOI: 10.1021/bi0346446. View

Leeds J, Dean C . Peptide deformylase as an antibacterial target: a critical assessment. Curr Opin Pharmacol. 2006; 6(5):445-52. DOI: 10.1016/j.coph.2006.06.003. View

Leszczyniecka M, Bhatia U, Cueto M, Nirmala N, Towbin H, Vattay A . MAP1D, a novel methionine aminopeptidase family member is overexpressed in colon cancer. Oncogene. 2006; 25(24):3471-8. DOI: 10.1038/sj.onc.1209383. View

Giglione C, Serero A, Pierre M, Boisson B, Meinnel T . Identification of eukaryotic peptide deformylases reveals universality of N-terminal protein processing mechanisms. EMBO J. 2000; 19(21):5916-29. PMC: 305796. DOI: 10.1093/emboj/19.21.5916. View

Escobar-Alvarez S, Gardner J, Sheth A, Manfredi G, Yang G, Ouerfelli O . Inhibition of human peptide deformylase disrupts mitochondrial function. Mol Cell Biol. 2010; 30(21):5099-109. PMC: 2953058. DOI: 10.1128/MCB.00469-10. View

10.

Giglione C, Pierre M, Meinnel T . Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol Microbiol. 2000; 36(6):1197-205. DOI: 10.1046/j.1365-2958.2000.01908.x. View

11.

Lee M, Antczak C, Li Y, Sirotnak F, Bornmann W, Scheinberg D . A new human peptide deformylase inhibitable by actinonin. Biochem Biophys Res Commun. 2003; 312(2):309-15. DOI: 10.1016/j.bbrc.2003.10.123. View

12.

Carroll J, Fearnley I, Walker J . Definition of the mitochondrial proteome by measurement of molecular masses of membrane proteins. Proc Natl Acad Sci U S A. 2006; 103(44):16170-5. PMC: 1621045. DOI: 10.1073/pnas.0607719103. View

13.

Antczak C, Shum D, Escobar S, Bassit B, Kim E, Seshan V . High-throughput identification of inhibitors of human mitochondrial peptide deformylase. J Biomol Screen. 2007; 12(4):521-35. PMC: 2234356. DOI: 10.1177/1087057107300463. View

14.

Serero A, Giglione C, Sardini A, Martinez-Sanz J, Meinnel T . An unusual peptide deformylase features in the human mitochondrial N-terminal methionine excision pathway. J Biol Chem. 2003; 278(52):52953-63. DOI: 10.1074/jbc.M309770200. View

15.

Antczak C, Shum D, Bassit B, Frattini M, Li Y, de Stanchina E . Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase. Bioorg Med Chem Lett. 2011; 21(15):4528-32. PMC: 3139024. DOI: 10.1016/j.bmcl.2011.05.129. View

16.

Solbiati J, Miller J, Miller C, Cronan Jr J . Processing of the N termini of nascent polypeptide chains requires deformylation prior to methionine removal. J Mol Biol. 1999; 290(3):607-14. DOI: 10.1006/jmbi.1999.2913. View